Katie Rubino is a partner in the corporate department at Wiggin and Dana in Boston. She frequently represents clients on target discovery collaborations, assisting in structuring spin-offs, divestitures and out-licensing from pharma, hospital systems and academic research institutions. She also counsels life sciences companies developing pharmaceuticals, vaccines, medical devices, antibody products, digital health and medical devices and advises companies raising growth capital, merger and acquisition transactions and initial public offerings.